Valiant Laboratories

Valiant Laboratories Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Valiant Laboratories (VALIANTLAB.NS) as of Nov 4, 2026 is -84.39. In the previous year, Cash Conversion Cycle (CCC) was 74.66 — a change of -213.02% (lower).

Cash Conversion Cycle

-84.39

YoY

-213.02%

Last updated:

Cash Conversion Cycle (CCC) of Valiant Laboratories is 2026 -84.39 . Cash Conversion Cycle (CCC) of Valiant Laboratories was 2025 74.66 . It decreases by -213.02% lower compared to the previous year.

The Valiant Laboratories Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2021
-18.31 INR
Jan 1, 2022
91.95 INR
Jan 1, 2023
52.90 INR
Jan 1, 2024
57.61 INR
Jan 1, 2025
74.66 INR
Jan 1, 2026
-84.39 INR
The Valiant Laboratories Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-84.39-213.02%
74.66+29.60%
57.61+8.90%
52.90-42.46%
91.95-602.19%
-18.31—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valiant Laboratories Stock analysis

What does Valiant Laboratories do? Valiant Laboratories Ltd manufactures paracetamol API/bulk drug for pharmaceutical applications, targeting medical conditions such as headache, muscle ache, arthritis, back ache, toothache, cold, and fever. The company operates a single manufacturing facility at Tarapur industrial estate, approximately 150 km from Nhava Sheva Port (JNPT), producing specialty chemicals and pharma intermediates for domestic and international markets. Its subsidiary, VALIANT ADVANCED SCIENCES PRIVATE LIMITED, supports the company's operations in the pharmaceutical sector. The firm's primary revenue comes from selling paracetamol API and specialty chemicals to pharmaceutical companies and distributors globally. Manufacturing focuses on high-demand applications like pain relief and fever treatment, with products distributed across India and abroad. The company leverages its Tarapur facility's proximity to Nhava Sheva Port for efficient export logistics. Valiant Laboratories Ltd serves the pharmaceutical industry by supplying essential active ingredients, particularly paracetamol, which is widely used in over-the-counter medications. The company's manufacturing capabilities for specialty chemicals and pharma intermediates cater to both domestic and international clients seeking reliable API sources. Its single-location production model ensures focused resource allocation for consistent output quality. Valiant Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valiant Laboratories stock

Cash Conversion Cycle (CCC) of Valiant Laboratories is -84.39 in 2026.

Cash Conversion Cycle (CCC) of Valiant Laboratories changed from 74.66 to -84.39, representing a -213.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Valiant Laboratories since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Valiant Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Valiant Laboratories

All Key Metrics — Valiant Laboratories